We’ve often written about white bagging, but today’s spotlight article bears yet another look. A recent NASP survey reinforces what many in specialty pharmacy already know: while awareness of white bagging is high, operational execution continues to vex the field. According to the NASP survey, a majority of respondents report active struggles around logistics, coordination, and financial alignment.
Key Challenges
· Supply chain and inventory risk — White bagging shifts the burden of drug delivery timing and storage to the provider site (infusion clinic or hospital) necessitating patient-specific inventory and managing changes in dosing or therapy last minute that introduces waste, delays, and potential stockouts.
· Coordination complexity — Because the specialty pharmacy (external to the site) controls dispatch, close coordination is paramount to avoid canceled or deferred infusions.
· Liability and oversight gaps — When providers do not control procurement, they lose visibility into the handling, storage, and chain of custody of the drug — increasing safety and compliance risk.
· Payment misalignment — Although payers push white bagging to shift cost structures, providers often lack commensurate reimbursement for the extra handling, scheduling, and inventory burden.
Emerging Solutions and Mitigations
· Clear or ’in-system’ bagging models are gaining traction… the health system’s own specialty pharmacy procures and delivers to its clinics, maintaining internal control and reducing external dependencies.
· Stronger contracting and advance notice: Institutions are demanding advance payer notification, locked-in service-level agreements, and shared liability language in agreements.
· Technology solutions: Systems that better integrate scheduling, inventory forecasts, and real-time delivery tracking help reduce misfires.
· Advocacy and policy interventions: Professional bodies are pushing for rules that protect provider autonomy and patient safety, limiting when payers can mandate white bagging.
The article also addresses a trend that’s emerging alongside white bagging, that of “zero-priced drugs”… drugs or tiers of drugs for which the patient (or provider site) has no out-of-pocket cost. These often include generic or preferred brand drugs, or specific drug classes adding yet another gambit to this four-dimensional chess game.
While payers see cost and control upside, providers face significant operational, clinical, and financial risks. For specialty pharmacy executives and provider leaders, the key is to anticipate these tensions, negotiate rigorously, invest in systems, and preserve clinical flexibility as new distribution policies proliferate.
————————————————————————————-
